Clinical study of remdesivir has accelerated rapidly as health authorities and the biotech respond to the fast-spreading coronavirus epidemic, which has now spread to 37 countries.
For the China studies and the NIH trial, Gilead has donated supplies of remdesivir and lent its expertise. The clinical tests announced Wednesday will be run by the biotech itself, primarily in Asian countries but also in nations with high numbers of diagnosed cases.
